A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies.

Trial Profile

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2012

At a glance

  • Drugs R 763 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 02 Mar 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 02 Mar 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Mar 2012 Actual patients number is 124 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top